safety-lane.com 07105
chiropractic-lane.com
www.shopcbd-lane
NEWARK
http://www.healthy-lane.com/
Half of Teens Drop Below Obesity Cutoff With Semaglutide
Nearly half (45%) of adolescents assigned to semaglutide (Wegovy), a once-weekly glucagon-like peptide-1 (GLP-1) agonist, managed to lose enough weight to drop below the clinical threshold for obesity, according to a secondary analysis of the STEP TEENS (Semaglutide Treatment Effect in People With Obesity) trial.
By comparison, only 12.1% of adolescents with obesity taking placebo in the trial dropped below the obesity threshold.
The study also found that 74% of participants shifted down by at least one body mass index (BMI) category after receiving the GLP-1 agonist, compared with 19% of those taking placebo.
“In a practical sense, we see that semaglutide reduced weight to a level below what is defined as clinical obesity in nearly 50% of the teens in our trial, which is historically unprecedented with treatments other than bariatric surgery,” remarked Aaron Kelly, MD, co-director of the Center for Pediatric Obesity Medicine at the University of Minnesota, Minneapolis, who presented the latest data at this year’s European Congress on Obesity (ECO).
“There was a 22.7-higher odds of dropping below the obesity threshold if assigned to semaglutide versus odds on placebo [P < .0001], and a 23.5-fold higher odds of dropping BMI by one category if on semaglutide [P < .0001],” he reported.
This analysis follows the 2022 publication of the main results of STEP TEENS published in the New England Journal of Medicine, as reported by Medscape Medical News, which showed semaglutide helped adolescents lose weight. The drug was subsequently approved by the US Food and Drug Administration for the treatment of obesity in those aged 12 and over in January of this year.
The new analysis was presented at ECO and simultaneously published in Obesity.
via Blogger https://bit.ly/45jYY83
Recent Comments